Similar articles

• The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions.

  Hasteh F, Lin GY, Weidner N, Michael CW. Hasteh F, et al. Cancer Cytopathol. 2010 Apr 25;118(2):90-6. doi: 10.1002/cncy.20071. Cancer Cytopathol. 2010. PMID: 20209622
• Effusion cytology in the diagnosis of malignant epithelioid and biphasic pleural mesothelioma.

  Sherman ME, Mark EJ. Sherman ME, et al. Arch Pathol Lab Med. 1990 Aug;114(8):845-51. Arch Pathol Lab Med. 1990. PMID: 2375659
• The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.

  Illei PB, Ladanyi M, Rusch VW, Zakowski MF. Illei PB, et al. Cancer. 2003 Feb 25;99(1):51-6. doi: 10.1002/cncr.10923. Cancer. 2003. PMID: 12589646 Clinical Trial.
• Immunocytochemical typification of mesothelial cells in effusions: in vivo and in vitro models.

  Ferrandez-Izquierdo A, Navarro-Fos S, Gonzalez-Devesa M, Gil-Benso R, Llombart-Bosch A. Ferrandez-Izquierdo A, et al. Diagn Cytopathol. 1994;10(3):256-62. doi: 10.1002/dc.2840100313. Diagn Cytopathol. 1994. PMID: 7519540
• Cytogenetic analysis of effusions from malignant mesothelioma. A diagnostic adjunct to cytology.

  Granados R, Cibas ES, Fletcher JA. Granados R, et al. Acta Cytol. 1994 Sep-Oct;38(5):711-7. Acta Cytol. 1994. PMID: 8091903